Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $38.0 million.

  • Entrada Therapeutics' Shares Outstanding (Weighted Average) rose 1.65% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 1.65%. This contributed to the annual value of $37.4 million for FY2024, which is 12.14% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Shares Outstanding (Weighted Average) stood at $38.0 million, which was up 0.22% from $38.0 million recorded in Q2 2025.
  • Entrada Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $38.0 million during Q3 2025, with a 5-year trough of $31.3 million in Q1 2022.
  • In the last 3 years, Entrada Therapeutics' Shares Outstanding (Weighted Average) had a median value of $33.8 million in 2024 and averaged $35.3 million.
  • Data for Entrada Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 12.47% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Shares Outstanding (Weighted Average) stood at $33.1 million in 2022, then increased by 0.88% to $33.4 million in 2023, then rose by 12.14% to $37.4 million in 2024, then climbed by 1.65% to $38.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $38.0 million for Q3 2025, versus $38.0 million for Q2 2025 and $37.6 million for Q1 2025.